Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MORPHIC HOLDING, INC.

(MORF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Morphic Holding, Inc.
Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially first-in-class oral small molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an Alpha 4 and Beta 7-specific integrin inhibitor affecting inflammation, for the treatment of inflammatory bowel disease (IBD). It has also developed oral ╬▒vb6-specific integrin inhibitors including MORF-720 and MORF-627, for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The Company is using its MInT Platform to advance a pipeline of preclinical programs across a variety of therapeutic areas.

Number of employees : 89 people.
Managers
Name Title Age Since
Praveen P. Tipirneni, Dr. President, Chief Executive Officer & Director 51 2015
Marc Schegerin, Dr. Chief Operating & Financial Officer 44 2020
Bruce N. Rogers, Dr. Chief Scientific Officer 51 2016
Peter G. Linde, Dr. Chief Medical Officer 53 2020
Timothy A. Springer, Dr. Independent Director 72 -
Gustav A. Christensen Chairman 72 2016
Amir H. Nashat, Dr. Independent Director 47 2017
Nilesh Kumar Independent Director 43 2018
Joseph P. Slattery Independent Director 55 2019
Norbert W. Bischofberger, Dr. Independent Director 65 2019
Members of the board
Name Title Age Since
Gustav A. Christensen Chairman 72 2016
Timothy A. Springer, Dr. Independent Director 72 -
Amir H. Nashat, Dr. Independent Director 47 2017
Nilesh Kumar Independent Director 43 2018
Joseph P. Slattery Independent Director 55 2019
Praveen P. Tipirneni, Dr. President, Chief Executive Officer & Director 51 2015
Norbert W. Bischofberger, Dr. Independent Director 65 2019
Martin W. Edwards, Dr. Director 64 2020
Susannah Gray Independent Director 59 2021
Nisha Nanda, Dr. Independent Director 45 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 36,961,618 24,906,990 67.4% 0 0.0% 67.4%
Shareholders
NameEquities%
Timothy A. Springer 4,822,431 13.2%
Fidelity Management & Research Co. LLC 4,387,839 12.0%
Ecor1 Capital LLC 3,951,566 10.8%
Polaris Growth Management LLC 2,090,651 5.74%
Novo Holdings A/S (Investment Company) 2,050,446 5.63%
Invus Public Equities Advisors LLC 1,585,049 4.35%
GSK Equity Investments Ltd 1,431,551 3.93%
Omega Fund Management LLC 1,315,952 3.61%
Pfizer Inc. 1,265,635 3.47%
The Vanguard Group, Inc. 1,127,987 3.09%
Company contact information
Morphic Holding, Inc.
35 Gatehouse Drive A2
Waltham, MA 02451

Phone : +1.781.996.0955
Brand Portfolio
In partnership withAllbrands.markets
More brands of Morphic Holding, Inc.
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
MORPHIC HOLDING, INC.42.18%1 763
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741
ELI LILLY AND COMPANY46.91%224 871
ABBVIE INC.7.59%203 801
MERCK & CO., INC.-8.42%189 218
NOVARTIS AG-12.21%178 183
ASTRAZENECA PLC13.00%169 755
BRISTOL-MYERS SQUIBB COMPANY-13.54%119 040
SANOFI6.56%118 651
AMGEN INC.-13.50%112 022
GLAXOSMITHKLINE PLC13.64%101 121
CHUGAI PHARMACEUTICAL CO., LTD.-33.13%53 361
JIANGSU HENGRUI MEDICINE CO., LTD.-45.99%50 233
BAYER AG-7.55%49 298
DAIICHI SANKYO COMPANY, LIMITED-20.10%47 743
TAKEDA PHARMACEUTICAL COMPANY LIMITED-19.28%42 041
ASTELLAS PHARMA INC.11.64%29 077
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY41.85%23 535